AdipoGen Life Sciences

KUNB31

Name: KUNB31
Brand: AdipoGen Life Sciences
SKU: AG-CR1-3758
Price: 90.00 CHF
Availability: InStock

As low as CHF 90.00

In stock

Only %1 left

AG-CR1-3758-M0011 mgCHF 90.00

Specifications / Handling

More Information
Product Details
Synonyms	(4-Hydroxy-7-isopropylbenzo[d]isoxazol-5-yl)(isoindolin-2-yl)methanone
Product Type	Chemical
Properties
Formula	C₁₉H₁₈N₂O₃
MW	322.4
CAS	2220263-80-7
Purity Chemicals	≥98% (HPLC)
Appearance	White to off-white powder.
Solubility	Soluble in DMSO (≥2mg/ml).
InChi Key	MFZKTINXWPQHBG-UHFFFAOYSA-N
Smiles	O=C(C1=CC(C(C)C)=C(ON=C2)C2=C1O)N3CC(C=CC=C4)=C4C3
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
Safety Data Sheet	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product Description

KUNB31 is an isoform-selective potent inhibitor of HSP90β with an IC₅₀ value of 180nM and >50-fold selectivity over the isoforms HSP90α and GRP94. KUNB31 was shown to induce the degradation of HSP90β-dependent client proteins, but not those of HSP90α and GRP94. It showed anti-proliferative activity against NCI H23 (non-small cell lung cancer), UC3 (bladder cancer), and HT-29 (colon adenocarcinoma) cells. KUNB31 specifically induces the degradation of HSP90β-dependent client proteins (EGFR, HER2, CDK4, CDK6, CXCR4 etc.) in cells.
Heat-shock protein 90 (HSP90) is an abundant protein involved in many cellular signaling processes, including inflammation. HSP90 binds NLRP3 and regulates inflammasome activation and IL-1β secretion. HSP90 inhibitors are used to inhibit NLRP3-dependent inflammation and study inflammasome responses in disease. Recently, it has been shown that while NLRP3 WT does not need HSP90β, mutated NLRP3 proteins (except E567K), that are autoactivated and responsible for the disease cryopyrin-associated periodic syndromes (CAPS), need the chaperone HSP90β during their autoactivation. KUNB31 is used as a selective HSP90β inhibitor in such NLRP3 inflammasome studies to inhibit NLRP3 activity.

Product-specific References

Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor: A. Khandelwal, et al.; Nat. Commun. 9, 425 (2018)
Inhibitors of the NLRP3 inflammasome by HSP90 inhibitors: S. Nizami, et al.; Immunol. 162, 84 (2020)
Selective Inhibition of the Hsp90α isoform: S.J. Mishra, et al.; Angew. Chem. Int. Ed. Engl. 60, 10547 (2021)
Hiding in plain sight: Optimizing topoisomerase IIα inhibitors into Hsp90β selective binders: J. Dernovsek, et al.; Eur. J. Med. Chem. 280, 116934 (2024)
HSP90β controls NLRP3 autoactivation: L. Spel, et al.; Sci. Adv. 10, eadj6289 (2024)

Call	+41 61 926 6040
Fax	+41 61 926 6049